News
Alpha-1 Foundation congratulates Talecris Biotherapeutics as shares begin trading for the first time on Nasdaq
MIAMI – Alpha-1 Foundation President and CEO John W. Walsh today recognized Talecris Biotherapeutics as the company’s stock began trading for the first time on the Nasdaq stock market.
“The Alpha-1 Foundation wishes to congratulate Talecris and its employees on their Initial Public Offering. We appreciate the company’s continued commitment to provide safe and efficacious augmentation therapy for Alpha-1 Antitrypsin Deficiency for more than two decades,” said Walsh.
“I believe that access to additional capital will help support the ongoing development of the Alpha-1 community’s next-generation therapy – augmentation therapy by aerosol,” Walsh added.
